[Treatment of COVID-19 with Inhaled Glucocorticoids - Statement of the German Respiratory Society (DGP), the Austrian Society of Pneumology (ÖGP) and the German Society of Allergology and Clinical Immunology (DGAKI)]
- PMID: 34000741
- DOI: 10.1055/a-1488-5373
[Treatment of COVID-19 with Inhaled Glucocorticoids - Statement of the German Respiratory Society (DGP), the Austrian Society of Pneumology (ÖGP) and the German Society of Allergology and Clinical Immunology (DGAKI)]
Conflict of interest statement
Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
Comment on
-
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844996 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
